Skulle bare mangleđPho er underpriset
1 Like
2 skritt fram idag og ett tilbake imorgen? (Minst.)
Nej den skal videre op
1 Like
Lille bror Spetalen er pÄ ny inne i aksjen med selskapet Kristianro as.
Han bare ventet til den nĂŠrmet seg ATH igjenđ Sikkert lurt da for PHO er underpriset de luxe hvis det gĂ„r mot standard behandling over heler verden og soc
1 Like
For delt ikke at tÊnke pÄ hvis de lykkes med cervia
1 Like
Ser jo bra ut sÄ langt 
1 Like
Ikke sikkert markedet helt har skjĂžnt hva som skjer borte i Kina enda, men det kommer etter hvert.
DS har vÊrt Bull pÄ Asieris ganske lenge og utlisensieringen av bÄde Hexvix og Cevira tyder pÄ at ambisjonsnivÄet er hÞyt.
Siste melding fra Asieris:
Shanghai, China, May 20, 2021 â Asieris Pharmaceuticals (Asieris) announced today that it has signed a strategic collaboration agreement with Sinopharm. The two companies will jointly advance commercialization, logistics and supply chain services for the innovative products of Asieris. The first project under the partnerhsip will be the commercialization of HexvixÂź, which comes on the heels of the collaboration with Lecheng Sinopharm.
Hvem er sÄ Sinopharm:
China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with 128,000 employees and a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services.
Sinopharm owns over 1,100 subsidiaries and 6 listed companies which are Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., and China Traditional Chinese Medicine Holdings Co., Ltd.
Link: SINOPHARM > ABOUT US > About Us
Sinopharm er ikke akkurat en smÄgutt i Kinesisk sammenheng.
Men, sĂ„ kan jo hver og en filosofere litt over hva det betyr at âstatenâ i Kina er med pĂ„ dette lĂžpet.
4 Likes
Sinopharm er forresten selskapet bak den kinesiske Covid-vaksinen Sinovac, som er den desidert mest utbredte vaksinetypen i Asia. Den ble nylig ogsÄ godkjent av WHO. Det er med andre ord langt fra noen smÄgutt dette.
4 Likes
HĂžy omsetning i PHO i dag.
Samtidig ser det ut, som Arrowstreet tar til fornuft.
Shorten er redusert til 0,88 %
Men det var fredag. Ingen reduksjon hverken idag eller igÄr. De mÄ ha mye penger Ä slÞse bort, eller sÄ forventer de ny nedtur.
Selskapet som skal distribuere i Kina har 97 prosent refusjon fra det offentlige. Idag kom ny sol/partiet med forslag om 2.07 milliarder yen i refusjon for behandling av NON invassiv blĂŠre og cervixkreftđ€©
3 Likes
Yuanđ
Kilde?
Googleoversetter:
Yahong Pharmaceutical holds the 5th set of standard âapplicationâ science and technology innovation board to raise 2.07 billion yuan to increase new tumor drugs
Reduce text2021-05-26 18:12:49 Source: Shanghai Securities News · China Securities Net Author: Qi Doudou
Shanghai Securities News China Securities Network News (Reporter Qi Doudou) On May 26, the Shanghai Stock Exchange accepted Jiangsu Yahong Pharmaceutical Technology Co., Ltd. (referred to as âYahong Pharmaceuticalâ) science and technology innovation board application, the company plans to raise 2.07 billion yuan. So far, the number of sci-tech innovation board acceptance companies has reached 567.
According to the prospectus application draft, Asia Rainbow Medicine is a global innovative drug company that is about to enter the commercialization stage, focusing on urogenital system (Urogenital System) tumors and other major diseases. The company has established an in-depth product pipeline in the field of genitourinary research, especially with non-muscular invasive bladder cancer (NMIBC) as the first key market. It has built an advantageous product portfolio covering the diagnosis and treatment of NMIBC, and is committed to providing doctors and patients with The best integrated solution for diagnosis and treatment.
At present, the company is carrying out the research and development and registration of 9 products, of which 3 studies on 2 products are in phase III or critical clinical trials. APL-1202 is the worldâs first (First-in-Class) oral, reversible type II methionyl aminopeptidase (MetAP2) inhibitor to enter the anti-tumor critical/phase III clinical trial, and the first internationally The non-muscular invasive bladder cancer (NMIBC) oral targeted therapy that has entered pivotal/Phase III clinical trials is expected to fill the market gap in this therapeutic field. In May 2021, a Phase I/II clinical trial application was submitted to the US FDA for APL-1202 combined with tislelizumab for the treatment of myometrial invasive bladder cancer (MIBC).
APL-1702 is a photodynamic therapy drug-device combination product that is advanced to the international multi-center phase III clinical trial based on the global patent rights granted by Yahong Medicine from Photocure. It is used for non-surgical treatment including all HPV virus subtype infections. Cervical high-grade squamous intraepithelial lesion (HSIL, a high-grade cervical precancerous lesion). The partner Photocure has completed a number of phase I and phase II clinical trials of APL-1702 worldwide, and the test results show that the product has significant efficacy and good safety. The product will eliminate the impact of surgical treatment on the reproductive function of women of childbearing age. The company expects to be the first to submit a listing application for APL-1702 in China in the fourth quarter of 2022.
Since the company has not yet entered the commercialization stage with no revenue or profit, it chose the fifth set of listing criteria this time. This time the company plans to raise 2.07 billion yuan to invest in drugs, medical devices and supporting cream production projects, new drug research and development projects, marketing network construction projects, and supplementary working capital.
Prior to this issuance, the actual controller PAN KE directly held 28.14% of the companyâs shares, indirectly held 6.93% of the companyâs shares through Pan-Scientific, and indirectly controlled 5.30% of the companyâs shares through the employee shareholding platforms Taizhou Yahong and Taizhou Donghong, totaling Controls 40.37% of the companyâs shares.
In addition, there are many well-known PE/VC and listed companies in the shareholder list of Yahong Pharmaceutical, and the number of institutional shareholders exceeds 40. QM139, a subsidiary of Qiming Venture Capital, holds 2.94% of the companyâs shares and ranks the fifth largest shareholder; Tigermed holds 1.31% of the companyâs shares through Hangzhou Tiger; two state-owned shareholders, Taizhou Huacheng and Taizhou Dongfang, together hold 1.86%. The actual controller behind it is the Management Committee of Taizhou Pharmaceutical High-tech Industrial Development Zone.
10 Likes
En liten BLFC studie: Outpatient blue-light flexible cystoscopy.
Results: Bladder cancer was diagnosed in 29 out of 70 (41%) cases, among them 14/29 (48%) had malignant lesions seen only in blue light. The majority had carcinoma in situ (21/29). Normal findings were seen in 41 cases that underwent BLFC. During the further course, malignancy of the bladder was detected in six cases (9%) and malignancy of the upper urinary tract was detected in one case (1%). The majority of patients (93%) preferred the blue-light flexible cystoscopy performed at the outpatient clinic instead of the transurethral resection under general anaesthesia.
10 Likes
Ny klinikk oppfÞrt pÄ Cysview.
LDS Hospital
8th Ave C Street, Salt Lake City, UT 84143
19 Likes
Som Dan sa, deep pocketed krefter som stÄr bak Asieris, virker som de med enkelhet klarer Ä hente alle de penger de trenger pÄ veien frem mot Ä bli et kommersielt selskap
1 Like